Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Recruiting
- Conditions
- Breast NeoplasmHER2-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorBreast CancerBreast TumorsHormone Receptor Negative TumorTriple-Negative Breast Cancer (TNBC)Locally Advanced Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Phase 2
Not yet recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 126
- Registration Number
- NCT05577923
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 333
- Registration Number
- NCT05572645
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05561686
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Not Applicable
Not yet recruiting
- Conditions
- HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-10-03
- Target Recruit Count
- 50
- Registration Number
- NCT05560308
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Phase 3
- Conditions
- HER2+ Breast Cancer
- Interventions
- Drug: Anti-PD-1 monoclonal antibodyDrug: CDK4/6 inhibitorDrug: AI
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Target Recruit Count
- 120
- Registration Number
- NCT05429684
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳Jin Yang, Xi'an, Shaanxi, China
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Target Recruit Count
- 209
- Registration Number
- NCT05429294
- Locations
- 🇨🇳
Jin Yang, Xi'an, Shaanxi, China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Phase 2
Active, not recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Caigang Liu
- Target Recruit Count
- 136
- Registration Number
- NCT05426486
- Locations
- 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Phase 3
Recruiting
- Conditions
- HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 269
- Registration Number
- NCT05424835
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2
Not yet recruiting
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05411276
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath